News

Update on the DIAN-TU-002 Primary Prevention Trial

20 December 2022 Update on the DIAN-TU-002 Primary Prevention Trial The statement below is an update to the 15 November...

WashU, Eisai form drug discovery collaboration

The Source, Washington University in St. Louis - Dec 14, 2022

Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)

The statement below is in response to the 14 November 2022 announcement regarding the results from the GRADUATE I and...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease

Roche - Nov 14, 2022

Update on the DIAN-TU-001 Trial with E2814 and Investigational Lecanemab (Eisai Co., Ltd)

The statement below is in response to the 28 September 2022 announcement found on Eisai’s website. Eisai Co., Ltd. (Headquarters:...

LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE

Eisai Co., Ltd. - Sept 27 2022

Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease

F. Hoffmann-La Roche Ltd - June 16, 2022

Could drugs prevent Alzheimer’s? These trials aim to find out

Nature - Mar 9, 2022

Blood test for Alzheimer’s highly accurate in large, international study

The Source, Washington University in St. Louis - Feb 22, 2022

First Subject Enrolled in Phase II/III Study of Eisai’s Anti-MTBR Tau Antibody E2814 for Dominantly Inherited Alzheimer’s Disease (DIAD), conducted by DIAN-TU

Eisai Co., Ltd. - Jan 19 2022